InvestSMART

Dimerix Limited (ASX:DXB)

ALERT: Price-sensitive ASX Announcement for DXB
Current share price for DXB : $0.200 -0.04 (-16.67%)+
Announcement
Release
30 Jul 2026 8:49AM
Price at Release
$0.240
Full Release
download
Summary
Dimerix Limited, a biopharmaceutical company, announced its quarterly activities report for 30 June 2026. The company executed a significant licensing agreement with Everest Medicines for several Asian territories, expected to bring up to A$481 million. This increases their potential milestone payments from all agreements to A$1.9 billion. The ACTION3 Phase 3 study for DMX-200 in FSGS remains robustly powered. Dimerix has expanded its pipeline by acquiring DMX-652 and secured additional non-dilutive funding to support its development operations. The company is financially poised to continue its clinical trials with substantial backing.
Key Points
  • Dimerix executed a licensing agreement with Everest Medicines for Greater China, South Korea, and Southeast Asia.
  • Dimerix is eligible to receive up to approximately A$481 million from the Everest transaction.
  • The aggregate value of all licensing agreements increased to approximately A$1.9 billion in potential milestone payments.
  • The ACTION3 Phase 3 study of DMX-200 in FSGS remains statistically powered to demonstrate treatment effects.
  • Dimerix acquired DMX-652, expanding its kidney disease development pipeline.
  • U.S. patent granted for DMX-652, providing protection through at least 2043.
  • A$10 million non-dilutive funding secured to support pipeline expansion.
  • Dimerix is funded through to completion of the ACTION3 Phase 3 trial for DMX-200 and initiation of the Phase 2 trial for DMX-652.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.